Skip to main content

Treating the Chronic Pain Patient earlier in the Pathway

Project description

An implant to treat chronic pain

Following surgery, approximately 1% of patients will experience chronic pain. Current pharma treatments incur significant side effects including nausea and contribute to the opioid epidemic in the US. Chronic pain is the number one cause of long-term disability resulting in significant taxpayer costs of USD 635 billion and EUR 300 billiion to the United States and EU taxpayers respectively. The problem today is that Chronic Pain Patients are only considered for neurostimulation treatment once all other treatments fail at 5-7 years post diagnosis. The EU-funded CAPRI project will enable the universality of bioelectronics and treat the patient earlier in the pathway. The Capri device is performed under local anaesthetic and requires a single injection. Most importantly, the patient is discharged immediately after injection and self-manages at home.

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

CAPRI MEDICAL LIMITED
Address
55 Lansdowne Park
D04W2K0 Ballsbridge
Ireland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 396 489